Literature DB >> 3428673

Influence of olsalazine on gastrointestinal transit in ulcerative colitis.

S S Rao1, N W Read, C D Holdsworth.   

Abstract

The effect of olsalazine on stool output and the transit of a solid radiolabelled meal through the stomach, small intestine and colon was studied in six patients with ulcerative colitis intolerant of sulphasalazine. Olsalazine 250 mg four times daily significantly accelerated gastric emptying (mean +/- SD; 45.3 +/- 24.2 min v 67.3 +/- 33.1 min, p less than 0.05), mouth to caecum transit time (242 +/- 41 min v 325 +/- 33 min, p less than 0.02) and whole gut transit time (60.5 +/- 26 h v 37.8 +/- 17.8 h, p less than 0.05). No significant changes were seen in mean daily stool weight (215 +/- 41 g v 162 +/- 62 g) and mean daily stool frequency (2.2 +/- 0.6 v 2.4 +/- 1.8). None of these patients developed diarrhoea, but acceleration of gastric and intestinal transit may be responsible for the diarrhoea reported in some patients taking this drug.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3428673      PMCID: PMC1433672          DOI: 10.1136/gut.28.11.1474

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  15 in total

1.  Faecal stasis and diverticular disease in ulcerative colitis.

Authors:  K N Jalan; R J Walker; R J Prescott; S T Butterworth; A N Smith; W Sircus
Journal:  Gut       Date:  1970-08       Impact factor: 23.059

2.  Sulfasalazine-induced exacerbation of ulcerative colitis.

Authors:  A G Schwartz; S R Targan; A Saxon; W M Weinstein
Journal:  N Engl J Med       Date:  1982-02-18       Impact factor: 91.245

3.  Capacity of the human colon to absorb fluid.

Authors:  J C Debongnie; S F Phillips
Journal:  Gastroenterology       Date:  1978-04       Impact factor: 22.682

4.  Transit of a meal through the stomach, small intestine, and colon in normal subjects and its role in the pathogenesis of diarrhea.

Authors:  N W Read; C A Miles; D Fisher; A M Holgate; N D Kime; M A Mitchell; A M Reeve; T B Roche; M Walker
Journal:  Gastroenterology       Date:  1980-12       Impact factor: 22.682

5.  Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties.

Authors:  H Sandberg-Gertzén; G Järnerot; W Kraaz
Journal:  Gastroenterology       Date:  1986-04       Impact factor: 22.682

6.  Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine.

Authors:  S S Rao; P A Cann; C D Holdsworth
Journal:  Scand J Gastroenterol       Date:  1987-04       Impact factor: 2.423

7.  Distribution and metabolism in healthy volunteers of disodium azodisalicylate, a potential therapeutic agent for ulcerative colitis.

Authors:  C P Willoughby; J K Aronson; H Agback; N O Bodin; S C Truelove
Journal:  Gut       Date:  1982-12       Impact factor: 23.059

8.  Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns.

Authors:  P A Cann; N W Read; C Brown; N Hobson; C D Holdsworth
Journal:  Gut       Date:  1983-05       Impact factor: 23.059

9.  Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine.

Authors:  P A van Hees; J H Bakker; J H van Tongeren
Journal:  Gut       Date:  1980-07       Impact factor: 23.059

10.  Olsalazine in active ulcerative colitis.

Authors:  W S Selby; G D Barr; A Ireland; C H Mason; D P Jewell
Journal:  Br Med J (Clin Res Ed)       Date:  1985-11-16
View more
  9 in total

1.  Olsalazine and GI transit in UC.

Authors:  S Meyers
Journal:  Gut       Date:  1988-05       Impact factor: 23.059

Review 2.  Drug-induced gastrointestinal disorders.

Authors:  H L Philpott; S Nandurkar; J Lubel; P R Gibson
Journal:  Frontline Gastroenterol       Date:  2013-06-19

3.  Effects of olsalazine and sulphasalazine on jejunal and ileal water and electrolyte absorption in normal human subjects.

Authors:  A H Raimundo; D H Patil; P G Frost; D B Silk
Journal:  Gut       Date:  1991-03       Impact factor: 23.059

4.  Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study.

Authors:  S S Rao; S A Dundas; C D Holdsworth; P A Cann; K R Palmer; C L Corbett
Journal:  Gut       Date:  1989-05       Impact factor: 23.059

Review 5.  Pharmacokinetic considerations in gastrointestinal motor disorders.

Authors:  G S Hebbard; W M Sun; F Bochner; M Horowitz
Journal:  Clin Pharmacokinet       Date:  1995-01       Impact factor: 6.447

6.  Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment of ulcerative colitis. The Danish Olsalazine Study Group.

Authors:  S Kiilerich; K Ladefoged; T Rannem; P J Ranløv
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

Review 7.  Newer 5-aminosalicylic acid based drugs in chronic inflammatory bowel disease.

Authors:  G Järnerot
Journal:  Drugs       Date:  1989-01       Impact factor: 9.546

8.  Dextran Carrier Macromolecules for Colon-specific Delivery of 5-Aminosalicylic Acid.

Authors:  P K Shrivastava; A Shrivastava; S K Sinha; S K Shrivastava
Journal:  Indian J Pharm Sci       Date:  2013-05       Impact factor: 0.975

9.  Synthesis and evaluation of mutual azo prodrug of 5-aminosalicylic acid linked to 2-phenylbenzoxazole-2-yl-5-acetic acid in ulcerative colitis.

Authors:  Jamal A Jilani; Maha Shomaf; Karem H Alzoubi
Journal:  Drug Des Devel Ther       Date:  2013-07-31       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.